Urodynamix Warrant Exercise Raises $900,000

VANCOUVER, British Columbia, August 14, 2007 - Urodynamix Technologies Ltd. (TSX-V:URO) today announced receipt of an additional $897,600 in gross proceeds from the exercise of share purchase warrants issued as part of a private placement in 2005.

A total of 94% of the outstanding warrants were exercised. As a result, Urodynamix currently has approximately $3.8 million of cash on hand to fund operations and working capital requirements.

"We are very pleased with the success of our warrant financing strategy, which has allowed us to successfully complete several important clinical studies and accelerate the development and commercialization of our URO-NIRS Bladder Monitor technology," said Barry Allen, President and CEO. "This funding represents yet another vote of confidence in our business model and provides further scope to support the development and launch of our innovative medical technology in the months ahead."

Urodynamix currently has outstanding 81,302,893 common shares and 6,909,000 incentive stock options.

About Urodynamix Technologies Ltd.

Urodynamix is developing a portfolio of non-invasive diagnostic products for large and growing global healthcare markets. The Company is currently developing medical devices that use near-infrared spectroscopy (NIRS) to aid in the diagnosis and treatment of urological conditions, intra-abdominal hypertension and compartment syndrome, erectile dysfunction and vascular diseases. Urodynamix's disruptive technology has the potential to beneficially affect more than 200 million people worldwide.

For further information, please contact:

Craig Pamplin, PhD, CFA

Director, Corporate Development and Communications

Urodynamix Technologies Ltd.

Tel: (604) 638-0247

Email: cpamplin@urodynamix.com

www.urodynamix.com